Department of Neurosurgery, Padua University Hospital, Via Giustiniani 2, 35128 Padova, Italy.
J Neurooncol. 2012 Jan;106(1):33-41. doi: 10.1007/s11060-011-0639-9. Epub 2011 Jul 2.
We recently described a three-layer concentric model of a glioblastoma (GBM) related to a specific distribution of molecular and phenotypic characteristics driven by the intratumoral hypoxic gradient in which the cancer stem cells niche is located in the hypoxic necrotic core of the tumour. The purpose of this study was to investigate the relationship between O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and MGMT expression in GBM samples collected according to the three-layer concentric model. Multiple tissue samples were obtained, by means of image-guided surgery, from the three concentric layers of newly diagnosed GBM. Two samples from each layer were collected from 12 patients (total 72 samples). Immunohistochemical analysis was performed on formalin-fixed paraffin-embedded tissue samples. The methylation status of the MGMT promoter was determined by methylation-specific polymerase-chain-reaction analysis. In all tumours, MGMT protein expression decreased progressively from the inner to the outer layer, and methylation of the MGMT promoter was unrelated to tumour layer. In particular, the MGMT promoter was unmethylated in all layers in 41.7% of tumours, methylated in all layers in 25%, and variably methylated in the three layers in 33.3%. We recorded concordance between MGMT expression and MGMT promoter methylation status within the GBM in only 58.8% of the samples collected. Our data suggest that both MGMT expression and promoter methylation data may be variable throughout GBM and that they may, consequently, depend on the site of surgical sample collection, even in the same patient. However, whereas MGMT expression is pre-operatively predictable when sampling is performed according to the three-layer concentric model, MGMT promoter methylation is not. These results must be considered when sample collection is performed for assessment of MGMT data.
我们最近描述了一个与特定分子和表型特征分布有关的胶质母细胞瘤(GBM)三层同心模型,这种分布由肿瘤内缺氧梯度驱动,其中癌症干细胞位于肿瘤缺氧性坏死核心中。本研究的目的是调查根据三层同心模型收集的 GBM 样本中 O(6)-甲基鸟嘌呤-DNA 甲基转移酶(MGMT)启动子甲基化状态与 MGMT 表达之间的关系。通过图像引导手术,从新诊断的 GBM 的三个同心层中获得多个组织样本。从每个层的两个样本中采集了 12 名患者(总共 72 个样本)的样本。对福尔马林固定石蜡包埋组织样本进行免疫组织化学分析。通过甲基化特异性聚合酶链反应分析确定 MGMT 启动子的甲基化状态。在所有肿瘤中,MGMT 蛋白表达从内层到外层逐渐降低,而 MGMT 启动子的甲基化与肿瘤层无关。特别是,在 41.7%的肿瘤中,MGMT 启动子在所有层中均未甲基化,在 25%的肿瘤中在所有层中均甲基化,在 33.3%的肿瘤中在三个层中均可变甲基化。我们仅在收集的 58.8%样本中记录了 GBM 中 MGMT 表达和 MGMT 启动子甲基化状态之间的一致性。我们的数据表明,即使在同一患者中,MGMT 表达和启动子甲基化数据在整个 GBM 中可能是可变的,并且它们可能取决于手术样本采集的部位。然而,当根据三层同心模型进行采样时,MGMT 表达可以术前预测,而 MGMT 启动子甲基化则不能。在评估 MGMT 数据时进行样本采集时,必须考虑这些结果。